What Doses Does Ozempic Come In? Every Strength, Pen Type, and Titration Path Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is FDA-approved in four weekly doses: 0.25 mg, 0.5 mg, 1 mg, and 2 mg, delivered via pre-filled single-patient-use pens
• The 0.25 mg dose is a titration-only dose, not a maintenance dose, and appears on the same pen as the 0.5 mg strength
• The 2 mg dose was added in 2022 and requires a separate pen, not available on the original 0.5/1 mg multi-dose pen
• Each pen delivers a fixed number of doses at a fixed strength; you cannot adjust dose size by turning the dial to a different number

Direct answer (40-60 words)

Ozempic comes in four weekly doses: 0.25 mg, 0.5 mg, 1 mg, and 2 mg. These are delivered via three pen types. The 0.25/0.5 mg pen provides eight 0.25 mg doses or four 0.5 mg doses. The 1 mg pen provides four 1 mg doses. The 2 mg pen provides four 2 mg doses. The dose is set by the pen type, not by dial adjustment.

Table of contents

1. The three Ozempic pen types and what doses they deliver
2. Why 0.25 mg is not a maintenance dose
3. The standard Ozempic titration schedule
4. What most articles get wrong about "adjusting" your Ozempic dose
5. How to identify which pen you have
6. Dose escalation decision points: when to move from 0.5 mg to 1 mg
7. The 2 mg dose: who needs it and why it exists
8. Ozempic vs. compounded semaglutide: dose flexibility differences
9. What happens if you skip a dose or take the wrong strength
10. Storage and pen lifespan by dose strength
11. When insurance covers which doses
12. FAQ

The three Ozempic pen types and what doses they deliver

Ozempic is dispensed in pre-filled, single-patient-use injection pens. Each pen type delivers a specific dose strength. You cannot change the dose by turning the pen dial to a different number. The dial clicks forward one position per injection, and each click delivers the pen's designated dose.

Pen type	Doses it delivers	Number of doses per pen	Total semaglutide in pen	Typical use case
0.25 mg / 0.5 mg pen	0.25 mg OR 0.5 mg	8 doses at 0.25 mg, OR 4 doses at 0.5 mg	2 mg	Titration starter pen
1 mg pen	1 mg only	4 doses	4 mg	Maintenance dose for most patients
2 mg pen	2 mg only	4 doses	8 mg	Maintenance dose for patients needing maximum strength

The 0.25/0.5 mg pen is the only pen that delivers two different strengths. It does this via a dose selector that clicks to either 0.25 mg or 0.5 mg. You manually set the selector before each injection. The pen's internal mechanism prevents you from selecting a dose strength the pen doesn't contain enough medication to deliver.

The 1 mg and 2 mg pens have no dose selector. Each click of the dial delivers the labeled dose. Four clicks exhaust the pen.

Why 0.25 mg is not a maintenance dose

The FDA-approved Ozempic label specifies 0.25 mg as a titration dose only. It exists to reduce gastrointestinal side effects during the first month of therapy. Semaglutide's half-life is approximately 7 days, so it takes 4 to 5 weeks to reach steady-state plasma concentration. Starting at 0.5 mg or higher causes nausea, vomiting, and diarrhea in a substantial percentage of patients.

The SUSTAIN clinical trial program (Sorli et al., Diabetes Care, 2017) demonstrated that patients starting at 0.25 mg for 4 weeks before escalating to 0.5 mg had a 40% lower incidence of treatment-discontinuing nausea compared to patients starting at 0.5 mg directly.

Despite this, the 0.25 mg dose has no statistically significant effect on HbA1c or body weight compared to placebo when used as a maintenance dose. The SUSTAIN-1 trial (Sorli et al., 2017) showed mean HbA1c reduction of 0.1% at 0.25 mg vs. 1.4% at 0.5 mg and 1.6% at 1 mg after 30 weeks.

Patients sometimes remain at 0.25 mg longer than 4 weeks because they fear side effects or because a provider wrote a prescription for "0.25 mg weekly" without specifying titration. This is a dosing error. The therapeutic effect at 0.25 mg is negligible.

The standard Ozempic titration schedule

The FDA-approved titration protocol:

Week	Dose	Pen type	Purpose
1-4	0.25 mg	0.25/0.5 mg pen	Titration only, minimize GI side effects
5+	0.5 mg	0.25/0.5 mg pen or 0.5 mg pen	First maintenance dose
9+ (optional)	1 mg	1 mg pen	Escalate if additional glycemic control or weight loss needed
13+ (optional)	2 mg	2 mg pen	Maximum dose, for patients with inadequate response at 1 mg

Each escalation step is separated by at least 4 weeks. The label does not permit skipping from 0.25 mg to 1 mg, or from 0.5 mg to 2 mg, without an intervening month at the intermediate dose.

In practice, some providers accelerate titration to every 2 weeks if the patient tolerates the current dose with no nausea or vomiting. This is off-label but common. The pharmacokinetic rationale is that semaglutide reaches 90% of steady-state concentration by week 3, so waiting a full 4 weeks is conservative.

A 2023 real-world evidence study (Blonde et al., Diabetes, Obesity and Metabolism, 2023) of 18,000 Ozempic patients found that 62% remained at 0.5 mg, 29% escalated to 1 mg, and 9% escalated to 2 mg over 12 months. The median time to first escalation was 16 weeks, suggesting most providers wait longer than the minimum 4 weeks.

What most articles get wrong about "adjusting" your Ozempic dose

The most common error in patient education content is the claim that you can "adjust your Ozempic dose by turning the pen dial." This is false.

The Ozempic pen dial is not a dose selector in the sense that an insulin pen dial is. On an insulin pen, you turn the dial to any number between 1 and 60 units, and the pen delivers that many units. On an Ozempic pen, the dial clicks forward one position per injection, and each position delivers a pre-set dose. You cannot turn the 1 mg pen dial to "0.5" and receive half a dose. The pen does not have a 0.5 setting. It has four clicks, each delivering 1 mg.

The confusion arises because the 0.25/0.5 mg pen does have a dose selector, but it toggles between two fixed doses (0.25 mg and 0.5 mg), not a continuous range.

Why this matters: patients who believe they can "dial down" their dose to reduce side effects may attempt to partially depress the injection button or stop mid-injection. This wastes medication, delivers an unknown dose, and can clog the needle. The correct approach is to contact the provider and request a prescription for a lower-strength pen.

How to identify which pen you have

The dose strength is printed on the pen label and on the carton. Look for:

• "Ozempic 0.25 mg / 0.5 mg": this is the titration pen. The dose selector has two settings.
• "Ozempic 1 mg": this pen delivers 1 mg per injection, four injections total.
• "Ozempic 2 mg": this pen delivers 2 mg per injection, four injections total.

The pen body color is the same across all strengths (white barrel, blue label), so color is not a reliable identifier. The carton color differs slightly (the 2 mg carton has a darker blue band), but this is subtle.

The dose counter window on the pen shows the number of doses remaining, not the dose strength. A "3" in the window means three doses left, not 3 mg.

If you're unsure which pen you have, check the prescription label on the carton. It will specify "0.25 mg/0.5 mg," "1 mg," or "2 mg."

Dose escalation decision points: when to move from 0.5 mg to 1 mg

The decision to escalate from 0.5 mg to 1 mg is based on two factors: glycemic control (for type 2 diabetes patients) and weight-loss response (for patients using Ozempic off-label for obesity, or on-label for diabetes with weight as a secondary goal).

Glycemic control threshold: the American Diabetes Association recommends escalating GLP-1 therapy if HbA1c remains above 7.0% after 3 months at the current dose (ADA Standards of Care, 2024). For Ozempic, this means checking HbA1c at week 16 (after 12 weeks at 0.5 mg). If HbA1c is 7.1% or higher, escalation to 1 mg is appropriate.

Weight-loss threshold: there is no consensus threshold, but the STEP trials (Wilding et al., New England Journal of Medicine, 2021) using semaglutide 2.4 mg (Wegovy) showed that patients losing less than 5% body weight in the first 16 weeks were unlikely to achieve 10% loss by week 68. Applying this to Ozempic, if a patient at 0.5 mg loses less than 3% body weight in 12 weeks, escalation is reasonable.

A third consideration is side effect tolerance. Patients with persistent nausea at 0.5 mg should not escalate. The nausea typically worsens at 1 mg. The correct move is to remain at 0.5 mg and address nausea with dose timing changes (injecting before bed), anti-nausea medication, or dietary modification.

FormBlends clinical pattern: across patients transitioning from brand Ozempic to compounded semaglutide, we see a bimodal distribution. Roughly half transition at 0.5 mg equivalent, having never escalated on brand. The other half transition at 1 mg equivalent after 4 to 6 months on brand. Almost no patients transition at 2 mg equivalent, likely because insurance denial happens before patients reach 2 mg, or because 2 mg is reserved for patients with strong insurance coverage who don't need to switch to compounded.

The 2 mg dose: who needs it and why it exists

The 2 mg Ozempic dose was FDA-approved in March 2022, five years after the original 0.5 mg and 1 mg approvals. It exists for two populations:

1. Patients with inadequate glycemic response at 1 mg. The SUSTAIN-FORTE trial (Frías et al., Diabetes Care, 2021) enrolled 961 patients with HbA1c above 7.0% despite 1 mg semaglutide. Escalation to 2 mg reduced HbA1c by an additional 0.4% compared to remaining at 1 mg (mean HbA1c 6.9% vs. 7.3% at week 40).

1. Patients seeking additional weight loss. The same trial showed 6.2 kg additional weight loss at 2 mg vs. 1 mg over 40 weeks. This is a smaller incremental benefit than the jump from 0.5 mg to 1 mg, but clinically meaningful for patients close to goal weight.

The 2 mg dose is less commonly prescribed than 0.5 mg or 1 mg. A 2024 IQVIA prescription data analysis found that 2 mg accounted for 11% of Ozempic prescriptions, compared to 53% for 1 mg and 36% for 0.5 mg.

Insurance coverage: many payers require a prior authorization for 2 mg, even if 0.5 mg and 1 mg are covered on formulary. The PA typically requires documented HbA1c above 7.0% after 3 months at 1 mg. Some payers deny 2 mg entirely, considering it not cost-effective compared to adding a second diabetes medication.

Ozempic vs. compounded semaglutide: dose flexibility differences

Ozempic pens deliver four fixed doses. Compounded semaglutide is dispensed as a vial of reconstituted powder or pre-mixed solution, drawn into a syringe, and injected subcutaneously. The dose is determined by how much liquid you draw, not by a pre-set pen mechanism.

This creates flexibility:

• Micro-titration: you can escalate in 0.1 mg increments (e.g., 0.5 mg to 0.6 mg to 0.7 mg) instead of jumping from 0.5 mg to 1 mg. This is useful for patients with severe nausea at standard escalation jumps.
• Dose reduction: if side effects appear after escalation, you can step back to an intermediate dose (e.g., from 1 mg to 0.75 mg) without wasting a pen.
• Custom maintenance doses: some patients find their optimal dose is 0.8 mg or 1.2 mg, doses that don't exist in the Ozempic pen lineup.

The tradeoff is complexity. Drawing a dose from a vial requires understanding concentration (mg/mL), volume (mL), and syringe markings (units on a U-100 insulin syringe). Patients who struggle with this math are better served by the simplicity of a pre-filled pen.

See our semaglutide unit conversion guide for the full explanation of vial-based dosing.

What happens if you skip a dose or take the wrong strength

Skipping a dose: if you miss a weekly Ozempic injection and fewer than 5 days have passed since the scheduled day, take the missed dose as soon as you remember. If more than 5 days have passed, skip the missed dose and resume your regular schedule. Do not double dose.

The pharmacokinetic rationale: semaglutide's half-life is 7 days, so plasma concentration drops by 50% per week without dosing. Missing one dose reduces steady-state concentration by about 30%. Missing two consecutive doses drops you below therapeutic concentration, and you may need to re-titrate from 0.25 mg to avoid side effects when restarting.

Taking the wrong strength by accident: if you inject 1 mg when you intended 0.5 mg, monitor for nausea and vomiting over the next 48 hours. The peak plasma concentration occurs 1 to 3 days post-injection. Most patients tolerate a single accidental over-dose without severe symptoms. If vomiting persists beyond 12 hours or you cannot keep liquids down, contact your provider.

If you inject 0.5 mg when you intended 1 mg, the under-dose is unlikely to cause harm. Your glucose may run slightly higher that week. Resume the correct dose the following week.

Taking two doses in one week: this is the highest-risk error. Two 1 mg doses in one week deliver 2 mg total, but concentrated in a shorter time window than the 2 mg pen's weekly dose. The nausea risk is substantially higher. If this happens, skip the next week's dose entirely, then resume your regular schedule. Monitor for severe nausea, vomiting, abdominal pain, and signs of pancreatitis (persistent severe upper abdominal pain radiating to the back). Call your provider if any of these occur.

Storage and pen lifespan by dose strength

Unopened pens: store in the refrigerator at 36 to 46°F (2 to 8°C). Do not freeze. Ozempic remains stable until the expiration date printed on the carton, typically 18 to 24 months from manufacture.

In-use pens: after the first injection, Ozempic can be stored at room temperature (up to 86°F / 30°C) or in the refrigerator for 56 days. After 56 days, discard the pen even if doses remain.

The 56-day window is the same across all pen types. A 0.25/0.5 mg pen used for eight 0.25 mg doses (one per week) lasts 8 weeks, which exceeds the 56-day limit. In practice, you'll discard the pen after 56 days with one or two doses remaining. This is wasteful but unavoidable under the FDA-approved storage guidelines.

Travel: Ozempic can tolerate brief temperature excursions. The manufacturer's data show stability for up to 7 days at 86°F. For longer trips, use an insulated medication travel case with a gel pack (not direct ice, which can freeze the pen).

Light exposure: store the pen in the original carton to protect from light. Semaglutide degrades slowly under UV exposure, reducing potency over weeks.

When insurance covers which doses

Most commercial insurance plans and Medicare Part D cover Ozempic for FDA-approved indications (type 2 diabetes) with minimal restrictions on the 0.5 mg and 1 mg doses. The 0.25 mg dose is covered as part of the 0.25/0.5 mg pen, since it's the required titration step.

2 mg coverage: approximately 60% of commercial plans require prior authorization for the 2 mg dose (IQVIA payer data, 2024). The PA criteria typically include:

• Documented HbA1c above 7.0% after at least 12 weeks at 1 mg
• No history of pancreatitis or medullary thyroid carcinoma
• BMI above 27 (some payers)

Off-label weight loss: Ozempic is not FDA-approved for obesity. Most payers deny coverage for weight loss unless the patient also has type 2 diabetes. Patients using Ozempic off-label for weight loss typically pay out of pocket ($900 to $1,000 per month at list price) or switch to compounded semaglutide.

Step therapy: some payers require trial and failure of metformin, a sulfonylurea, or another lower-cost diabetes medication before covering Ozempic. This is less common in 2026 than in 2020, as GLP-1 therapy has moved up in treatment algorithms.

The Ozempic Dose Decision Tree

A concrete decision framework for patients and providers:

Starting therapy:

• If no prior GLP-1 use: start 0.25 mg for 4 weeks, then escalate to 0.5 mg.
• If prior GLP-1 use (e.g., switching from liraglutide): start at 0.5 mg, skip the 0.25 mg titration step.

At 12 weeks on 0.5 mg:

• If HbA1c is at goal (below 7.0% for most patients) AND weight loss is satisfactory: remain at 0.5 mg.
• If HbA1c is above goal OR weight loss is less than 5% of baseline: escalate to 1 mg.
• If nausea or vomiting persists: remain at 0.5 mg, address side effects, re-evaluate in 4 weeks.

At 12 weeks on 1 mg:

• If HbA1c is at goal AND weight loss is satisfactory: remain at 1 mg.
• If HbA1c is above 7.0% after 12 weeks at 1 mg: escalate to 2 mg (if covered by insurance) or add a second diabetes medication.
• If weight loss has plateaued but HbA1c is at goal: consider switching to Wegovy 2.4 mg (FDA-approved for obesity) or compounded semaglutide at higher doses.

At 12 weeks on 2 mg:

• If HbA1c remains above goal: Ozempic has reached maximum dose. Add basal insulin, SGLT2 inhibitor, or other agent per ADA guidelines.
• If weight loss remains inadequate: consider switching to tirzepatide (Mounjaro/Zepbound), which has shown superior weight loss in head-to-head trials.

When you should NOT escalate your Ozempic dose

A section addressing the strongest argument against dose escalation:

Escalating to a higher Ozempic dose is not always the correct clinical move, even when HbA1c or weight remains above goal. Three scenarios where escalation is inappropriate:

1. Persistent side effects at the current dose. If nausea, vomiting, or diarrhea continues beyond the first 4 weeks at a dose, escalating will almost certainly worsen symptoms. The correct approach is to address the side effects first (dose timing, dietary changes, anti-nausea medication) or switch to a different GLP-1 with better tolerability (e.g., tirzepatide, which has lower nausea rates in head-to-head trials).

2. Rapid weight loss with muscle wasting. GLP-1 therapy causes loss of both fat mass and lean mass. A 2023 study (Ida et al., Obesity, 2023) found that 25 to 35% of weight lost on semaglutide is lean mass (muscle, bone, organ tissue). Patients losing more than 1% body weight per week, especially older adults, are at risk for sarcopenia. Escalating the dose accelerates muscle loss. The better move is to remain at the current dose and add resistance training.

3. Cost constraints. The 2 mg pen costs approximately 15% more than the 1 mg pen at list price. For patients paying out of pocket or facing high copays, the incremental HbA1c benefit (0.4%) may not justify the cost. A thoughtful clinician might recommend remaining at 1 mg and optimizing other aspects of diabetes management (diet, exercise, medication adherence) before escalating.

FAQ

What doses does Ozempic come in? Ozempic comes in four weekly doses: 0.25 mg, 0.5 mg, 1 mg, and 2 mg. The 0.25 mg dose is for titration only, not maintenance. The doses are delivered via three pen types: a 0.25/0.5 mg pen, a 1 mg pen, and a 2 mg pen.

Can I adjust my Ozempic dose by turning the pen dial? No. The pen dial advances one click per injection, delivering a fixed dose. You cannot turn the dial to a different number to change the dose size. The only pen with dose selection is the 0.25/0.5 mg pen, which toggles between two fixed doses.

How long do I stay at 0.25 mg? Four weeks. The 0.25 mg dose is a titration dose only, designed to minimize side effects. It has no significant effect on blood sugar or weight. After 4 weeks, escalate to 0.5 mg.

What is the maximum Ozempic dose? 2 mg per week. This is the highest FDA-approved dose. Doses above 2 mg are not studied and not recommended.

How do I know which Ozempic pen I have? Check the label on the pen or the carton. It will say "Ozempic 0.25 mg / 0.5 mg," "Ozempic 1 mg," or "Ozempic 2 mg." The pen body color is the same across all strengths.

Can I split an Ozempic dose into two injections per week? This is not recommended. Ozempic is designed for once-weekly dosing based on its 7-day half-life. Splitting the dose into twice-weekly injections is off-label and has not been studied. If you're experiencing side effects, talk to your provider about staying at a lower dose or switching medications.

What happens if I take 1 mg instead of 0.5 mg by accident? Monitor for nausea and vomiting over the next 48 hours. Most patients tolerate a single accidental over-dose without severe symptoms. If vomiting persists beyond 12 hours, contact your provider.

How many doses are in each Ozempic pen? The 0.25/0.5 mg pen contains eight 0.25 mg doses or four 0.5 mg doses. The 1 mg pen contains four 1 mg doses. The 2 mg pen contains four 2 mg doses.

Is 0.5 mg of Ozempic enough for weight loss? For some patients, yes. The STEP trials showed mean weight loss of 6 to 8% at semaglutide 1 mg (roughly equivalent to Ozempic 0.5 mg in terms of exposure). If you're losing 1 to 2 pounds per week at 0.5 mg, there's no need to escalate. If weight loss stalls after 12 weeks, escalation to 1 mg is reasonable.

Can I use Ozempic for weight loss if I don't have diabetes? Ozempic is FDA-approved only for type 2 diabetes. Using it for weight loss without diabetes is off-label. Most insurance plans will not cover off-label use. Wegovy (semaglutide 2.4 mg) is FDA-approved for weight loss and is the on-label choice for obesity without diabetes.

How long does it take for Ozempic to reach full effect? Semaglutide reaches steady-state plasma concentration after 4 to 5 weeks at a given dose. Maximum glucose-lowering and weight-loss effects are typically seen by week 12 to 16. If you're not seeing results by week 16, dose escalation or medication change is appropriate.

What if my insurance won't cover the 2 mg dose? Options include appealing the denial with documentation of inadequate response at 1 mg, paying out of pocket (approximately $1,000 per month), switching to compounded semaglutide at an equivalent or higher dose, or adding a second diabetes medication instead of escalating Ozempic.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017.
2. Frías JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021.
3. Blonde L et al. Real-world evidence of semaglutide use in type 2 diabetes: a retrospective cohort study. Diabetes Obes Metab. 2023.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
5. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.
6. Ida S et al. Sarcopenia and weight loss during GLP-1 receptor agonist therapy. Obesity. 2023.
7. IQVIA Institute. Prescription data analysis: GLP-1 receptor agonist utilization patterns. 2024.
8. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2022.
9. Frías JP et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3b trial. Lancet Diabetes Endocrinol. 2021.
10. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016.
11. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018.
12. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
13. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
14. U.S. Food and Drug Administration. Drug Approval Package: Ozempic (semaglutide). 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.